NEW YORK (TheStreet) -- On Thursday, shares of Celgene (CELG - Get Report) climbed 5.9% after beating revenue and EPS estimates. On Friday, the stock continued its move higher on what Cramer, the co-manager of the Action Alerts PLUS portfolio, called an "amazing" earnings report.
"This thing is going right to $120," Cramer said on CNBC's "Cramer's Mad Dash" TV show, adding that Gilead Sciences (GILD will likely trade higher as well.
He said Celgene's CEO Robert Hugin is doing a great job, as the company continues to develop more and more drugs and treatments.
Cramer likes the biotech industry, as the group continues to move higher. He pointed out that Regeneron (REGN is also making new all-time highs, as it surpasses $400 per share.
Finally, he said Bristol-Myers Squibb (BMY "delivered a very fine quarter" and is a core stock that investors can plan to hold for the next five years. The company has a very good anti-cancer franchise and is doing a lot of things right, Cramer concluded.
-- Written by Bret Kenwell